376
- Kaye CI, Committee on Genetics, Accurso F, et al. Newborn screening fact sheets. Pediatrics.
2006;118:e934. - Krone N, Arlt W. Genetics of congenital adrenal hyperplasia. Baillieres Best Pract Res Clin
Endocrinol Metab. 2009;23:181–92. - Melmed S, Williams R. Williams textbook of endocrinology. Philadelphia: Elsevier/Saunders;
2011. - Mercè Fernández-Balsells M, Muthusamy K, Smushkin G, et al. Prenatal dexamethasone use
for the prevention of virilization in pregnancies at risk for classical congenital adrenal hyper-
plasia because of 21-hydroxylase (CYP21A2) defi ciency: a systematic review and meta-
analyses. Clin Endocrinol (Oxf). 2010;73:436–44. - Merke DP, Bornstein SR. Congenital adrenal hyperplasia. Lancet. 2005;365:2125–36.
- Merke DP, Keil MF, Jones JV, Fields J, Hill S, Cutler Jr GB. Flutamide, testolactone, and
reduced hydrocortisone dose maintain normal growth velocity and bone maturation despite
elevated androgen levels in children with congenital adrenal hyperplasia. J Clin Endocrinol
Metab. 2000;85:1114–20. - Nimkarn S, Lin-Su K, New M. Steroid 21-hydroxylase defi ciency congenital adrenal hyper-
plasia. Pediatr Clin North Am. 2011;58:1281–300. - Speiser P, Azziz R, Baskin L, Ghizzoni L, Hensle T, Merke D, et al. Congenital adrenal hyper-
plasia due to steroid 21-hydroxylase defi ciency: an Endocrine Society Clinical Practice
Guideline. J Clin Endocrinol Metab. 2010;95:4133–60.
10 Congenital Adrenal Hyperplasia